<DOC>
	<DOCNO>NCT02665416</DOCNO>
	<brief_summary>This open-label , two-part study design assess safety , PK , PD , therapeutic activity RO7009789 combination vanucizumab participant metastatic solid tumor amenable standard treatment . Part I ( dose escalation ) design establish maximum tolerate dose ( MTD ) RO7009789 combination . Part II ( expansion ) intend characterize safety clinical activity profile RO7009789 among indication-specific cohort .</brief_summary>
	<brief_title>Study Evaluating Safety , Pharmacokinetics ( PK ) , Pharmacodynamics ( PD ) , Therapeutic Activity RO7009789 With Vanucizumab Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Part I : Advanced/metastatic , histologically confirm solid tumor amenable standard therapy ( except prostate squamous nonsmall cell lung cancer [ NSCLC ] ) Part II : Histologically confirm advanced platinumresistant ovarian carcinoma ( aPROC ) , metastatic gastric carcinoma ( mGC ) , metastatic cervical carcinoma ( mCC ) , nonresectable metastatic colorectal cancer ( mCRC ) , metastatic pancreatic carcinoma ( mPC ) , metastatic triplenegative breast carcinoma ( mTNBC ) Greater equal ( &gt; /= ) 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy &gt; /= 16 week Adequate hematologic , renal , hepatic , cardiovascular function Measurable disease per RECIST Agreement use adequate contraceptive measure among men among woman childbearing potential Prostate cancer squamous nonsmall cell lung cancer ( NSCLC ) Recent systemic anticancer treatment Prior treatment antiprogrammed death ( PD ) 1 antiprogrammed death ligand ( PDL ) 1 therapeutic antibody , vanucizumab , compound target cluster differentiation ( CD ) 40 Part II : Treatment target vascular endothelial growth factor ( VEGF ) receptor within 12 month prior enrollment Systemic immunosuppressive medication within 2 week prior D1 C1 Unacceptable/unresolved toxicity prior anticancer therapy Bisphosphonate therapy symptomatic hypercalcemia History vein thrombosis/thromboembolism , use anticoagulant within 7 day prior study drug Significant cardiovascular cerebrovascular disease within 6 month prior D1 C1 History bowel obstruction , perforation , abscess Prior radiotherapy pelvis abdomen , rectosigmoid involvement , bowel involvement among participant aPROC Severe nonhealing wound/ulcer bone fracture Pregnant lactate woman History autoimmune disease Human immunodeficiency virus ( HIV ) hepatitis B C Severe infection receipt live/attenuated vaccine within 4 week prior D1 C1 Other significant malignancy within 3 year prior D1 C1 Allergy/hypersensitivity study drug Prior allogeneic bone marrow solid organ transplant Other conditions/findings may contraindicate use study drug Major surgery within 4 week prior study drug Known clinically significant liver disease History hemoptysis bleed diathesis , know coagulopathies Known symptomatic untreated central nervous system ( CNS ) malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>